Alleviating Carbohydrate-Counting Burden in T1DM Using Artificial Pancreas and Empagliflozin
Status:
Completed
Trial end date:
2019-11-21
Target enrollment:
Participant gender:
Summary
One of the challenges in the design of the artificial pancreas (AP) is preventing
postprandial hyperglycemia. Beyond algorithmic solutions, one countermeasure to postprandial
hyperglycemia that may enhance performance of the AP is the use of adjunctive-to-insulin
medications such as those in the Sodium Glucose-Linked Transporter 2 inhibitor class. This
study evaluates whether use of oral empagliflozin on the background of single-hormone AP can
improve postprandial blood glucose control. The investigators will test this hypothesis in a
cross-over trial design by comparing open-label empagliflozin versus placebo in the setting
of AP on separate study days that involve carbohydrate counting, simple meal announcement and
no meal announcement strategies.
Phase:
N/A
Details
Lead Sponsor:
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Collaborators:
Canadian Diabetes Association Institut de Recherches Cliniques de Montreal McGill University Health Center McGill University Health Centre/Research Institute of the McGill University Health Centre